Association of Human Epidermal Growth Factor Receptor 2 with Radiotherapy Resistance in Patients with T1N0M0 Breast Cancer.
Association of Human Epidermal Growth Factor Receptor 2 with Radiotherapy Resistance in Patients with T1N0M0 Breast Cancer.
复制标题
DOI：
10.4048/jbc.2013.16.3.266
复制
发表时间：
2013-09
影响因子：
2.4
通讯作者：
Korean Breast Cancer Society
中科院分区：
文献类型：
--
作者：
Kim HA;Kim EK;Kim MS;Yu JH;Lee MR;Lee HK;Suh YJ;Noh WC;Korean Breast Cancer Society
临床前研究表明，人表皮生长因子受体2（HER 2）状态与放疗（RT）抵抗有关。在这项研究中，我们根据RT的使用和HER 2状态评估了韩国T1 N 0 M0乳腺癌队列的总生存率。我们分析了1999年至2007年期间参加韩国乳腺癌协会登记计划的11，552例浸润性乳腺癌患者的数据。分析TNM分期、雌激素受体状态、孕激素受体状态、HER 2状态、手术方法和RT的使用情况。中位随访期为51个月。仅在HER 2（-）组中观察到RT后总生存期的显著改善。在该组中，未接受RT的患者的10年总生存率为95.5%，接受RT的患者为96.3%（p=0.037）。相反，在HER 2（+）组中，RT与生存获益无关（p=0.887）。多变量分析显示，RT与HER 2（-）组的死亡率降低显著相关（风险比，0.738; 95%置信区间，0.549-0.993; p=0.045）。我们发现，术后RT与HER 2（+）乳腺癌患者的生存获益无关，这表明HER 2（+）乳腺癌可能对RT具有耐药性。
Preclinical studies have shown that human epidermal growth factor receptor 2 (HER2) status is associated with resistance to radiotherapy (RT). In this study, we evaluated the overall survival of a T1N0M0 breast cancer cohort in Korea according to the use of RT and the HER2 status. We analyzed data collected from 11,552 patients with invasive breast cancer who were enrolled in the Korean Breast Cancer Society Registration Program between 1999 and 2007. Data on the TNM stage, estrogen receptor status, progesterone receptor status, HER2 status, operation method, and the use of RT were analyzed. The median follow-up period was 51 months. A significant improvement in overall survival after RT was observed only in the HER2(-) group. In this group, the 10-year overall survival rate was 95.5% for patients who did not receive RT and 96.3% for patients who received RT (p=0.037). In contrast, in the HER2(+) group, RT was not associated with a survival benefit (p=0.887). Multivariate analysis showed that RT was significantly associated with a reduction in mortality in the HER2(-) group (hazard ratio, 0.738; 95% confidence interval, 0.549-0.993; p=0.045). We found that postoperative RT was not associated with a survival benefit in HER2(+) breast cancer patients, suggesting that HER2(+) breast cancers could be RT resistant.
登录
查看更多内容
影响因子：
168.9
作者：
Overgaard, M;Jensen, MB;Mouridsen, HT
通讯作者：
Mouridsen, HT
影响因子：
4.6
作者：
Jung KW;Park S;Kong HJ;Won YJ;Lee JY;Seo HG;Lee JS
通讯作者：
Lee JS
影响因子：
45.3
作者：
Kyndi, Marianne;Sorensen, Flemming B.;Overgaard, Jens
通讯作者：
Overgaard, Jens
影响因子：
3.8
作者：
Lee, Jung Ah;Kim, Kwan-Il;Lee, Eun Sook
通讯作者：
Lee, Eun Sook
影响因子：
3.6
作者：
No, Mina;Choi, Eun Jung;Kim, In Ah
通讯作者：
Kim, In Ah